Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fludarabine is a small molecule chemotherapeutic drug classified as a purine nucleoside analog and antimetabolite[3][5][8]. It is not a receptor, enzyme, transporter, or endogenous protein target, but rather a compound that is structurally similar to adenosine and interferes with DNA replication and repair by inhibiting enzymes such as DNA polymerase, ribonucleotide reductase, and DNA primase[1][3][5]. It is used to treat cancers of the blood, notably chronic lymphocytic leukemia, via cytotoxic effects on rapidly dividing cells. The identification of "Fludarabine" as a target is incorrect, as it refers to a drug and not a molecular target or receptor.
Fludarabine interferes with DNA replication and repair by inhibiting enzymes such as DNA polymerase, ribonucleotide reductase, and DNA primase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fludarabine.